CA Patent

CA3192145A1 — Bridged tricyclic carbamoylpyridone compounds and uses thereof

Assigned to Gilead Sciences Inc · Expires 2022-04-07 · 4y expired

What this patent protects

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): (I) including stereoisomers and pharmaceutically acceptable salts thereof. Methods associated with the preparation and use of the …

USPTO Abstract

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): (I) including stereoisomers and pharmaceutically acceptable salts thereof. Methods associated with the preparation and use of the disclosed compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
CA3192145A1
Jurisdiction
CA
Classification
Expires
2022-04-07
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.